Assertio Holdings (ASRT) Cash & Equivalents (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Cash & Equivalents came in at $33.7 million in Q1 2026, down 3.69% year-on-year from $35.0 million in Q1 2025, and up 229.58% quarter-over-quarter from $10.2 million in Q4 2025.
Assertio Holdings (ASRT) Cash & Equivalents (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Cash & Equivalents across 8 years of filings, most recently posting $33.7 million for Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $33.7 million, down 3.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.7 million (down 3.69% YoY), and the FY2025 annual result was $10.2 million, down 79.78% from the prior year.
- Cash & Equivalents came in at $33.7 million for Q1 2026 at Assertio Holdings, up from $10.2 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $80.7 million in Q1 2024 to a low of $10.2 million in Q4 2025.
- The 5-year median for Cash & Equivalents is $52.3 million (2022), against an average of $53.6 million.
- Across the five-year window, Cash & Equivalents jumped 76.42% in 2022 and slumped 79.78% in 2025, its largest moves.
- Assertio Holdings' Cash & Equivalents stood at $64.9 million in 2022, then gained by 13.09% to $73.4 million in 2023, then slumped by 31.12% to $50.6 million in 2024, then plunged by 79.78% to $10.2 million in 2025, then jumped by 229.58% to $33.7 million in 2026.
- The last three Cash & Equivalents figures came in at $33.7 million (Q1 2026), $10.2 million (Q4 2025), and $38.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 3.74 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.94 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 1.28 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 40.42 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 266.50 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 428.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 351.55 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 222.27 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 498.58 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | 33.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.71 Mn |
| Dec 31, 2025 | 10.23 Mn |
| Sep 30, 2025 | 38.50 Mn |
| Jun 30, 2025 | 47.09 Mn |
| Mar 31, 2025 | 35.00 Mn |
| Dec 31, 2024 | 50.59 Mn |
| Sep 30, 2024 | 37.98 Mn |
| Jun 30, 2024 | 44.74 Mn |
| Mar 31, 2024 | 80.74 Mn |
| Dec 31, 2023 | 73.44 Mn |
| Sep 30, 2023 | 76.89 Mn |
| Jun 30, 2023 | 70.18 Mn |
| Mar 31, 2023 | 68.60 Mn |
| Dec 31, 2022 | 64.94 Mn |
| Sep 30, 2022 | 64.83 Mn |
| Jun 30, 2022 | 52.26 Mn |
| Mar 31, 2022 | 61.39 Mn |
| Dec 31, 2021 | 36.81 Mn |
| Sep 30, 2021 | 58.73 Mn |
| Jun 30, 2021 | 54.43 Mn |